AIP
CRSP icon

Alexis Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Alexis Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-98
Closed -$6.35K – 99
2025
Q3 		$6.35K Buy
+98
New +$5.63K ﹤0.01% 83
2025
Q1 		– Sell
-98
Closed -$3.86K – 52
2024
Q4 		$3.86K Buy
+98
New +$4.63K ﹤0.01% 77

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alexis Investment Partners's CRSP Position: Q4 2025 in Review

Alexis Investment Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 98 shares — an estimated $6.35K sold.

Alexis Investment Partners first reported a position in CRSP in Q4 2024 and held it in 2 quarters. The position peaked at $6.35K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Alexis Investment Partners reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Alexis Investment Partners sold 98 CRISPR Therapeutics shares in Q4 2025, an estimated $6.35K.
  • Alexis Investment Partners first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 2 quarters.
  • Alexis Investment Partners's CRISPR Therapeutics position peaked at $6.35K in Q3 2025.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Alexis Investment Partners's 13F filing for Q4 2025, filed 29 Jan 2026.